Impact of nanotechnology on drug delivery.
By O. Farokhzad, Robert Langer. ACS Nano, 2009
3,104 citations recorded by the source corpus.
Subfields: Biomaterials, Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/e7f7108c95d937344e3a265591a653d745832fa2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomaterials
In Biomedical Engineering
In Molecular Biology
Citations in the corpus
- Progress in electrochemical synthesis of magnetic iron oxide nanoparticles (2014, methodology): “The sol–gel rout is generally an appropriate chemical method (wet) for the generating of metal oxides nanostructures [118–120].”
- Zinc Oxide Nanoparticles for Selective Destruction of Tumor Cells and Potential for Drug Delivery Applications (2010, background): “Nanotechnology may make it possible to improve the delivery of poorly water-soluble drugs, target delivery of drugs to specific cell or tissue sites, co-deliver two or more drugs, and aid in the visualization of drug site delivery by combining therapeutic agents with imaging modalities [99].”
- Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Together, these factors explain why active targeting strategies cannot radically change the biodistribution profiles of nanomaterials [157-159] and why the blood circulation times of ligand-decorated NPs need to be optimized to achieve optimal targeting [4, 33, 160].”
- An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites (2019, background): “However, some simulations([44]) argued that ligand-functionalized NPs enhance their interactions with leaky vessels to the detriment of deeper tumour tissues.”
- Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures (2017, methodology): “Significant expansion of this sector is expected in the upcoming years [41].”
- Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile (2012, background): “Targeted nanoparticles (TNPs) have the potential to overcome the toxicity and efficacy limitations associated with traditional cytotoxic agents and newer-generation molecularly targeted drugs by trafficking a greater fraction of the administered drug directly to cancer cells in a controllable and tu”